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Aggregates of Pseudomonas aeruginosa form a protective barrier against antibiotics and the immune 
system. These barriers, known as biofilms, are associated with several infectious diseases. One of the 
main components of these biofilms is alginate, a homo- and hetero-polysaccharide that consists of 
β-D-mannuronate (M) and α-L-guluronate (G) units. Alginate lyases degrade this sugar and have been 
proposed as biotherapeutic agents to dissolve P. aeruginosa biofilms. However, there are contradictory 
reports in the literature regarding the efficacy of alginate lyases against biofilms and their synergistic 
effect with antibiotics. We found that most positive reports used a commercial crude extract from 
Flavobacterium multivorum as the alginate lyase source. By using anion exchange chromatography 
coupled to nano LC MS/MS, we identified two distinct enzymes in this extract, one has both polyM 
and polyG (polyM/G) degradation activities and it is similar in sequence to a broad-spectrum alginate 
lyase from Flavobacterium sp. S20 (Alg2A). The other enzyme has only polyG activity and it is similar in 
sequence to AlyA1 from Zobellia galactanivorans. By characterizing both of these enzymes together 
with three recombinant alginate lyases (a polyM, a polyG and a polyM/G), we showed that only 
enzymes with polyM/G activity such as Alg2A and A1-II’ (alginate lyase from Sphingomonas sp.) are 
effective in dissolving biofilms. Furthermore, both activities are required to have a synergistic effect 
with antibiotics.
Biofilms are complex and dynamic structures formed by different pathogens that cause chronic persistent and 
recurrent infections. Among 65–80% of human infections are associated with biofilms1–4. They are especially fre-
quent in pulmonary infectious diseases like cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), 
bronchiectasis and ventilator-associated pneumonia (VAP). The challenge of treating biofilm infections is the 
increased resistance of the bacteria within the biofilm to antimicrobial agents and host defense mechanisms5. The 
metabolic activity of the bacterial cells is low, resulting in slow-growing cells with radically downregulated cell 
division rates6. Therefore, antibiotics such as β-lactams, which are only active against dividing cells, are not very 
efficient at eradicating biofilm infections. These diseases are very difficult to manage therapeutically, as the mini-
mum effective bactericidal concentration of antibiotics for biofilm eradication in vivo is impossible to reach with-
out causing adverse effects and renal and/or hepatic injury. Moreover, many of the pathogenic bacterial strains 
are antibiotic resistant. In particular, critically ill patients who are intubated and on mechanical ventilation are at 
greater risk of developing VAP7. P. aeruginosa and Staphylococcus aureus are the primary causative pathogens of 
biofilm-associated pulmonary infections7,8.
When these bacteria grow in biofilms, they form an extracellular matrix that acts as a barrier against antibi-
otics and the host immune system9. In the lung of CF patients, P. aeruginosa generally transitions to a mucoid 
phenotype characterized by the overproduction of the exopolysaccharide alginate10. Alginate is the most abun-
dant extracellular matrix polysaccharide and consists of β-D-mannuronate (M) and α-L-guluronate (G) as mon-
omeric units. These units can be linked in three different kinds of blocks, poly β-D-mannuronate (polyM), poly 
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α-L-guluronate (polyG) or the heteropolymer (polyM/G)11. The alginate is O-acetylated at the C-2 and/or C-3 
positions in mannuronate residues12–14. The monomer composition and the acetylation change depend on the 
strains and the carbon source. Alginate is one of the most extensively studied P. aeruginosa virulence factors and 
it is associated with persistence in the chronically inflamed airway15–17. Therefore, when trying to identify possible 
drug targets, many studies have focused on the alginate production pathway or the degradation of alginate by 
enzymes18–23.
Biochemical characterization of different alginate lyases24–34 has revealed different polyM and polyG activi-
ties. The enzymes are classified into seven polysaccharide lyase (PL) families (PL5, 6, 7, 14, 15, 17, and 18) in the 
Carbohydrate-Active enzymes (CAZY) database35. Alginate lyases from family PL7 have been widely studied, 
and the crystal structures of several PL7 alginate lyases are solved36–38. Structural analysis shows that these lyases 
share a common β-sandwich fold consisting of two β-sheets, in which conserved amino acid residues compose 
a deep active cleft that is covered by two flexible lid loops36–38. This family comprises both endolytic and exolytic 
alginate lyases.
The substrate specificities of PL7 alginate lyases are also diverse, including polyG-specific, polyM-specific, and 
bifunctional enzymes. One example of a bifunctional PL7 alginate lyase from Sphingomonas sp. A1 is A1-II’39. 
With respect to the PL5 family, AlgL is a 40-kDa poly-β-D-mannuronate lyase from P. aeruginosa that preferen-
tially degrades deacetylated polyM via a β-elimination reaction, resulting in disaccharides and trisaccharides as 
its major products40,41. Purified alginate lyases from P. aeruginosa strains (AlgL) have polyG/M activity and have 
been shown to dissolve P. aeruginosa PAO1 strain biofilms25. Alginate lyases A1-I (PL5 + 7 family), A1-II (PL7 
family) and A1-III (PL5 family) from Sphingomonas sp. strain A1 can produce di- and trisaccharides as major 
final products from alginate42. In addition, an oligoalginate lyase of this bacterium can degrade alginate oligosac-
charides into their respective constituent monosaccharides43. A1-I is active against acetylated and non-acetylated 
alginates. A1-II, on the other hand, prefers polyG and non-acetylated alginate. A1-III efficiently liquefies polyM 
and acetylated alginates produced by mucoid cells.
Alginate lyase treatment has been shown to reduce viscosity both in cultures of clinical isolates and in CF 
sputum29; it strips biofilms from abiotic surfaces22,44, enhances phagocytosis of P. aeruginosa by human immune 
cells20,23,45, and improves the efficacy of various antipseudomonal antibiotics18,19,45,46. However, although multiple 
studies have reported that the biofilm inhibitory concentration (BIC) of antibiotics against P. aeruginosa biofilm 
cultures is lowered when combined with alginate lyase activity18–21,47, it was also shown that synergy between 
tobramycin and the A1-III and AlgL enzymes is completely decoupled from their catalytic activity47. This raises 
the question of whether it is their enzyme activity that is important for dissolving biofilms. Moreover, whilst 
different studies using commercial crude extracts containing alginate lyase activity have been shown to dissolve 
biofilms18–20,23, recent studies have shown that the recombinant AlgL enzyme does not show a significant antibi-
ofilm effect; its catalytic activity against alginate and acetylated alginate is not sufficiently high48. Thus, a careful 
reexamination of the alginate lyases responsible for the enzymatic activities present in these extracts could clarify 
whether these proteins can really be used to dissolve P. aeruginosa biofilms and reduce the required dose of anti-
biotics in CF patients.
Here, we purified five alginases. Four belong to the PL7 family: Alg2A and AlyA1 (both related to the ones 
found in the crude Sigma extract), A1-II’ and A1-II; and one to the PL5 family (A1-III). We have characterized 
their activities against polyG, polyM and polyM/G substrates. We also tested their capacity to dissolve biofilms of 
two P. aeruginosa strains (PAO1 wt and PAO1ΔmucA) and evaluated their synergistic effect when used in com-
bination with the antibiotic ciprofloxacin49. The efficacy of this fluoroquinolone in biofilms has been previously 
assessed by showing that antibiotic resistance of P. aeruginosa and S. aureus is critically increased during coculture 
biofilm growth50.
Results
Isolation and identification of the alginate lyase activities from the crude extract of 
Flavobacterium multivorum. The crude extract of Flavobacterium multivorum from Sigma (A1603 Sigma) 
was first fractionated using anion exchange and gel filtration chromatography. Then, the enzymatic activity of the 
different fractions was examined in a halo test done with the P. aeruginosa PAO1 wt cells (HT, Fig. 1A; Material 
and methods) and in an activity assay with brown seaweed alginate as the substrate (time point of 4 h; Fig. 1B). 
With both methods, we identified two separate activities in samples covering the range of fractions from B2 to 
B5 (Fig. 1A and B). The B2 and B5 fractions, as well as the surrounding ones, were analyzed by SDS gel electro-
phoresis (Fig. 1C). An upper band of approximately 40 kDa was enriched in fraction B5-B4 and a lower band of 
about 30 kDa was enriched in fractions B3 to B1, both being consistent across two different samples fractionated 
the same way.
Both bands were analyzed separately by mass spectrometry (MS) after trypsin and chymotrypsin digestions 
(Table 1 and Tables S1 to S8). As the source of the extract was unknown, identified spectra were assigned to 
peptide sequences by performing a de novo search51. To find protein sequences that had regions of similarity to 
the peptides found by MS, we used Basic Local Alignment search Tool (BLAST)52. BLAST search revealed that 
the peptide sequences from the lower SDS band were found in five orthologue alginate lyases (Tables S1 to S4). 
Peptides from the upper band were found in an alginate lyase (Zobellia galactanivorans (AlyA1); PL7 family)35 and 
in two proteins with no assigned function (hypothetical proteins; NCBI reference sequences: WP_012026046.1 
and WP_012026879.1) (Tables S5 to S8). Alg2A protein from Flavobacterium sp. S20 (PL7 family35); was selected 
as representative of the five alginate lyases detected in the lower band since its sequence contained the higher 
number of MS unique peptides (Fig. S1). These results suggested that enzymes similar to Alg2A and/or AlyA1, as 
well as proteins belonging to the two hypothetical protein families, could be responsible for degrading P. aerugi-
nosa alginate biofilms.
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Sequence analysis of AlyA1 and Alg2A. Alg2A (AEB69783.1) contains the highly conserved regions 
described for the PL7 family: (LIV)-XXWX-(LVI)-(TQN)LP, R-(SVA)-ELRE, NW, (IVLM)(IVLM)(AG)QIH, 
and YFKAG-X-G-Y-X-Q (Fig. S1), which compose the cavity of a jelly-roll β-sandwich structure where it is 
assumed to bind a suitable substrate (Fig. 2B). Alg2A has a QIH sequence in its catalytic center, which is a hall-
















: : : . *.: . . . .:
AlyA1 SYN-------TYSDDNYFYTDG--EWVYFKCYRGLGGSANSQNPRVELREMDNG-N-LAS
Alg2A GYPEILNYAEDKIASKYMYDDPKDKSVVFYAFPSGVTTANTHYSRSELRETMETGSNKVN
AI-II’    GYT-----------SQYFYTD-TDGAMTFWAPTTGGTTANSSYPRSELREMLDPSNSKVN




* .*. : : . . : ..**** : :. :::.
AlyA1 QFIGEENQSSG---------SVKLKISGYVTEEQGGSQTFSGYSLDTTYNCKLVYSGGYVE
Alg2A YWDKGKIRVKTKVLKDLNAPYKEMLLEHAWGDDEGRNFKEKIDLNTRFTLEVKVSDGRME
AI-II’   VFQDGQLDMQVKQNSDGT -------------GSDVHNYFTGIKLGDLYNMEIRVTDGVAY
: : . . : .*. :. :: :.*
AlyA1 LFMNGSSV---FRKKMEVDDLSENYFKVGNYLQSVKGASYTGSYGLVRIKNLSVTHN---
Alg2A VILNDTESLVYDDIHMKKWGIFENYFKAGNYFQSKT---P-GTFAKVKIYSLQVTH----
AI-II’    VTMNGDTRSVDFVGKDAGWKNLKYYFKAGNYVQDNT---STGGSAIAKLYSLSVSHSNLE
: :*. : : ***.***.*. . * . .:: .*.*:*
AlyA1 Alg2A
Figure 1. Activity of the Sigma extract fractions obtained after purification: (A) activity measured by the halo 
assay. We show images of the negative control (c-, no halo) and the halo formed with one representative fraction 
B2 of the Sigma extract (in blue, surrounding the disk). Scale bar corresponds to 10 mm (B) alginate lyase 
activity measured aafter 4 h of incubation and (C) SDS gel of the purified fractions that show activity. In the 
figure, a representative plot of two different experiments is shown.
Protease used for 
the digestion









Trypsin 529 157 134 73
Chymotrypsin 80 45 188 61
Table 1. Mass Spectrometry results of the two bands of the SDS gels run after the purification steps. The 
proteins extracted from the bands were digested with trypsin and chymotrypsin proteases. The table shows the 
number of peptides identified in each experiment and the Nr of proteins associated after Blast alignment.
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closest alginase in sequence which crystal structure has been determined (2 CWS) is the A1-II’ alginate lyase from 
Sphingomonas sp. A154.
Regarding AlyA1 (WP_013992548.1), sequence alignment shows that it is also a member of the PL7 fam-
ily and it contains the same elements as Alg2A (Fig. 2C) plus an extra domain of the family 32 (CBM32) that 
is required for carbohydrate binding55. Moreover, AlyA1 contains the QIH sequence that is characteristic of 
polyM/G alginases. However, it was classified in the SF3 subfamily of the PL7 family, which in theory, should only 
hydrolyze polyG substrates.
In the Fig. 2C we show the sequence alignment of Alg2A, AlyA1 and A1-II’. Alg2A has four longer loops than 
AlyA1 – three of which are located around the predicted substrate-binding site (Fig. 2A) – suggesting that this 
enzyme could recognize or bind to a different polymer structure. With respect to the residues that line the cavity, 
the conserved ones were associated with the putative active site, but the residues on one side are quite divergent 
(Fig. 2C-labeled in red). This reinforces the idea that although the catalytic mechanism of A1-II’ and Alg2A 
must be the same, Alg2A could recognize polymer structures of a different composition. Sequence analysis and 
comparison with A1-II’ alginate lyase shows a similar picture for AlyA1. The loops suroounding the cavity in the 
jelly roll where the substrate should bind are of different length and sequence than Alg2A, and the residues sur-
rounding the active site are conserved with those at one end being different (Fig. 2C-labeled in red). In this case 
the number of loops and residues that are different from the crystal structure is larger than Alg2A.
Characterization of the alginate-degrading activity of the identified proteins. Although we 
cloned both hypothetical proteins, we were only able to express and purify WP_012026046.1. Regarding the two 
alginate lyases (Alg2A (AEB69783.1) and AlyA1 (WP_013992548.1)) identified as possible orthologues of the 
alginate lyases from the extract, we were able to express and purify both. We also included other alginate lyases, 
namely A1-II’, A1-II (both PL7 family), and A1-III (PL5 family), to compare the activity of different enzymes 
by measuring the degradation of different substrates: brown seaweed, polyM and polyG alginate (Fig. 3; Table 2 
and Table 3). Alginate lyase activity was determined by following the increase in absorbance at 235 nm due to the 
formation of a carbon-carbon double bond at the end of the product generated from lyase-mediated cleavage 
of alginate. We also determined Kcat and Km constants for the different recombinant proteins with PolyG and 
PolyM substrates (Table 3; Fig. S2). No activity was found for the hypothetical protein (WP_012026046.1) against 
any of the studied substrates (data not shown).
Figure 2. Modelling of AlyA1 and Alg2A based on A1-II’ (2CWS) crystal structure. (A,B) Models of protein 
structures of AlyA1 and Alg2A, respectively. Loops involved in the interaction with the substrate are labeled 
in light blue. In dark blue we show the conserved residues in the cavity close to the putative active site. In red, 
non-conserved residues of the cavity. (C) ClustalW alignment of AlyA1 (WP_013992548.1), A1-II’ and Alg2A 
(AEB69783.1) protein sequences. Shadowed in dark blue are the residues that form the conserved substrate 
cavity and in red the important but non-conserved residues of this cavity. Loops important for substrate binding 
are labelled in light blue. Highly conserved regions described for PL7 family are marked with an asterisk. In 
bright pink, we show the unique aa sequences present in Alg2A or AlyA1 sequences.
5Scientific RepoRtS |         (2020) 10:9390  | https://doi.org/10.1038/s41598-020-66293-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
The two polyM/G alginases, A1-II’ and Alg2A, showed both polyG and polyM activity, but although having 
similar residues in the catalytic pocket, Alg2A showed more activity against both alginates than A1-II’. The spec-
ificity constant (Kcat/Km) calculated for each enzyme shows that A1-II’ is more specific for PolyG than Alg2A. 
Regarding PolyM substrate, we could determine the Kcat/Km specificity constant only for the A1-III enzyme, 
since in the case of the other proteins, saturation by substrate was not reached under the different concentrations 
tested (Fig. S2). Moreover, A1-II’ exhibited also activity against brown seaweed alginate, whereas Alg2A did not. 
AlyA1 has also the QIH sequence characteristic of polyM/G alginate lyases, but lacks activity against polyM 
alginate and revealed a similar activity to A1-II, displaying both enzymatic activities against polyG alginate and 
brown seaweed alginate. Regarding A1-III, it showed a great polyM activity a low activity against brown seaweed 
alginate and without any enzymatic activity against the polyG alginate.
This result confirms what was suggested by the sequence and structural analysis, that the loops surround-
ing the active site and the residues in the binding pocket far away from the active site play a role in substrate 
recognition.
Characterization of the alginate lyase activity of the candidate proteins on P. aeruginosa bio-
films. The enzymatic activity of alginate lyases was evaluated in P. aeruginosa biofilms grown for 96 hours 
before treatment. The experiment was performed in flow cell chambers where disaggregation was followed 
by imaging with a confocal microscope (Fig. 4). After treatment with different alginate lyases for 12 hours, 
Figure 3. Enzyme activity against different substrates. Alginate lyase enzyme kinetic activity against different 
substrates: (A) brown seaweed alginate, (B) polyM alginate and (C) polyG alginate. Error bars represent the 
standard deviation of three different replicates. The blank sample was obtained by adding buffer instead of 
enzyme and it was subtracted in all the samples.
Brown seaweed 
alginate PolyM PolyG
Slope r2 Slope r2 Slope r2
Alg2A 0.0069 0.969 0.0523 0.995 0.064 0.9936
A1-II 0.0389 0.9965 0.0084 0.9303 0.0651 0.9988
A1-II′ 0.0328 0.9985 0.0263 0.9999 0.0299 0.999
A1-III 0.088 0.9995 0.0834 0.9998 0.0024 0.9824
AlyA1 0.0304 0.9906 0.0034 0.9604 0.0312 0.999
Table 2. Slope values of the linear equations from the activity curves against different substrates for different 
enzymes. R-squared (r2) is the coefficient of determination, or the coefficient of multiple determination for the 
linear regression.
PolyG PolyM
Kcat Km (mg/ml) Kcat/Km Kcat Km (mg/ml) Kcat/Km
AlyA1 19.68 3.083 6.38
A1-II 20.55 1.866 11.01
A1-II′ 7.339 1.281 5.73
A1-III 0.4732 1.248 0.38 85.37 5.36 15.94
Alg2A 18.13 5.531 3.28
Table 3. Km and Kcat values of different enzimes in presence of PolyM and PolyG substrates.
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we measured the biomass, thickness and roughness of the biofilms formed by wild type P. aeruginosa PAO1 
(non-mucoid) and PAO1ΔmucA (mucoid strain) (Table S9). By measuring the difference in biofilm biomass 
between the untreated and treated samples, we were able to estimate the level of biofilm degradation by differ-
ent alginate lyases (Fig. 4). After 12 hours of treatment, the Alg2A and A1-II’ proteins resulted in the highest 
reduction of biofilm biomass (around 30%) of both P. aeruginosa strains, confirming their degradation activity 
(Fig. 4A). Interestingly, Alg2A was more efficient at degrading the biofilm of PAO1ΔmucA than that of PAO1 
wt. In contrast, A1-II’ degraded the biofilms formed by both strains to a similar extent. Although some biomass 
decrease was observed for A1-II in the PAO1 ∆mucA strain biofilm, the same alginate lyase had no reduction 
activity in the PAO1 wt biofilm. In the case of the A1-III alginate lyase, the reduction of the biomass was only 
observed in the PAO1 wt strain. However, the activity of these two enzymes (A1-II and A1-III) was lower when 
compared to the activity of the rest of the studied proteins (Alg2A and A1-II’). Confocal microscopy images 
Figure 4. Biofilm degradation activity. (A) The histogram shows the ability of different enzymes to degrade 
biofilms formed by P. aeruginosa PAO1 wt (solid bars) and PAO1ΔmucA (striped bars). The concentration of 
enzyme was the same in each sample (7.09 pmol/µl), that corresponds to 0.32 mg/ml for Alg2A; 0.14 mg/ml for 
A1-II; 0.22 mg/ml for A1-II’; and 0.23 mg/ml for A1-III. The values are normalized against the control sample 
(non-treated biofilm) that has 100% biomass. The decrease in the percentage of biomass reflects the effect of 
the treatment. The asterisk (*) indicates a significant difference (p < 0.05) when the sample is compared with 
the control. The (&) indicates a significant difference (p < 0.05) when the PAO1 wt strain is compared with 
PAO1ΔmucA. (B) Synergism between antibiotics and the AlyA1, A1-III and Alg2A alginate lyase proteins. The 
asterisk (*) indicates a significant difference (p < 0.05) when the sample is compared with the control. The (&) 
indicates a significant difference (p < 0.05) when alginase is compared with alginase + ciprofloxacin. The (∞) 
indicates a significant difference (p < 0.05) when the sample is compared with ciprofloxacin. (C) Sum of stack 
images and the corresponding orthogonal views of the confocal microscopy images of P. aeruginosa PAO1 wt 
and PAO1 ΔmucA biofilms treated with 7.09 pmol/µl of the different alginate lyases and 1 µg/ml of ciprofloxacin 
(CPX). Red and green colors show the P. aeruginosa dead and alive cells detected by the LIVE/DEAD staining 
kit, respectively. Scale bar corresponds to 50 µm.
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corroborated the abovementioned decreases in biomass (Fig. 4C, Supplementary Fig. S4). The ability of these 
enzymes to degrade biofilms was also compared with ciprofloxacin (CPX) antibiotic treatment, a benchmark 
treatment that results in approximately 15% biofilm reduction (Fig. 4A). After 12 hours of biofilm formation, 
A1-II’ is significantly more efficient at degrading the biofilm than pure CPX treatment.
In summary, we have shown that the broad spectrum polyM/G Alg2A and A1-II’ alginate lyases (PL7 family), 
but not the polyM or polyG alginate lyases like A1-II, (PL7) A1-III (PL5) and AlyA1 (PL7), can dissolve biofilms 
formed by P. aeruginosa.
Synergistic effects between alginate lyases and antibiotic treatment in the degradation of bio-
films. To gain insight into the role of alginate lyase activity in enhancing the effect of antibiotics, we treated 
P. aeruginosa PAO1 wt biofilms with Alg2A, A1-III or A1-II’ together with CPX and studied the impact on bio-
film biomass disaggregation. As shown in Fig. 4B, the combination of A1-II’ or Alg2A with CPX produced a 
synergistic effect on biofilm disaggregation, with more than a 10% increase in the reduction of the biofilm bio-
mass. Therefore, as previously shown, the combination of A1-III with CPX did not produced a synergistic effect 
(Fig. 4B). Thus, degradation of biofilm by enzymes with polyM/G activity is necessary to see an effect by CPX.
We discarded any antimicrobial activity by A1-II’ and Alg2A because no effect on the viability of PAO1 wt and 
PAO1ΔmucA strains was observed when grown in planktonic culture (Supplementary Fig. S3). Altogether, these 
results reveal that using Alg2A or A1-II’ alginate lyases to dissolve P. aeruginosa biofilms enhance antibiotic treatment.
Discussion
Alginate, one of the main virulence factors associated with P. aeruginosa biofilms, has been the main target over 
the last decades when attempting to uncover alternative treatments for CF. The alginate heterogeneity generated 
by different combinations of β-D-mannuronate (M) and α-L-guluronate (G), as well as their different acetylation 
profiles, make this exopolysaccharide very difficult to target.
Many studies demonstrating the antibiofilm activity of alginases have used crude cell extracts from P. aerug-
inosa20,23,45. Other groups used purified enzymes such as A1-III and AlgL, and concluded that the synergistic 
effects with antibiotics were independent of the enzyme activity47.
Upon testing the ability to degrade the biofilms of two different P. aeruginosa strains (one of them mucoid), by 
different alginases, representing the two major families and with different substrate specificities, we consistently 
found that the broad spectra alginate lyases were the most active enzymes. In fact, only when polyM/G enzymes 
were combined with ciprofloxacin antibiotic, the synergistic effect was observed. In contrast, enzymes which 
only have polyG and polyM degradation activities respectively, showed less activity towards the biofilms and no 
synergistic effect with CPX. This agrees with previous results that showed polyG that A1-III did not amplifly the 
effect of antibiotics against P. aeruginosa biofilms.
We also found that among polyM/G enzymes, A1-II’ was able to degrade the brown seaweed substrate more 
efficiently than Alg2A. Altogether, these results suggest that A1-II’ and Alg2A have a broad activity spectrum 
against different biofilms because they degrade a greater variety of alginate matrixes. In fact, a different endolytic 
reaction mode was assigned to the Alg2A enzyme because it produces a larger amount of penta-, hexa-, and 
hepta-saccharides from the hydrolysis products when compared with other alginate lyases.
In conclusion, we have unraveled the effect that different alginate lyases have on P. aeruginosa biofilm degra-
dation and we have identified Alg2A and A1-II’ as good disperal agents. We show an increase in the efficiency of 
antibiotic treatment when combined with Alg2A or A1-II’. Characterization of different alginate lyase proteins 
on biofilms reveled that Alg2A and A1-II’, despite having similar polyG/M and different activity against seaweed 
brown algynate, are the best candidates to use for degrading biofilms formed by different P. aeruginosa strains.
Methods
Ionic exchange and gel filtration chromatography. For anion exchange chromatography we used a 
HiTrap Q HP column (GE Healthcare product # 17-1153-01) in conjunction with an ÄKTA-FPLC system. The 
alginate lyase sample (Sigma #A1603) was dissolved in 20 mM Tris pH 8 as buffer A and applied to the pre-equil-
ibrated column. As buffer B, we used the same buffer with 1 M NaCl. After 20 ml, we increased the salt concentra-
tion to 500 mM over 50 ml and collected fractions of 1 ml.
For gel filtration chromatography a Superdex-75 column was used (GE Healthcare product # 17-5174-01) with 
20 mM Tris pH 8 and 150 mM NaCl as running buffer. The fraction size was 0.5 ml.
To achieve the presented resolution of proteins in the crude extract, we first performed an anion exchange chro-
matography, pooled fractions 37–42, 48–51 and 55–60, concentrated them and performed subsequent gel filtra-
tion. After the chromatographic runs, all fraction were supplemented with 10% glycerol to ensure protein stability.
Mass spectrometry of fractions. All experimental proteomics procedures were performed by the UPF/
CRG Proteomics Unit. We performed an initial tryptic digestion and peptide fingerprint MS analysis on the crude 
alginate lyase extract (Sigma A1603). Our aim was to screen for known toxins or other proteins with biofilm dis-
solving properties. We did not yield any reasonable lead from this. Therefore, we cut the protein bands identified 
as peaking using the halo activity test from an SDS gel. The bands were digested by trypsin or chymotrypsin and 
analyzed by nano-LC MS/MS. The resulting peaks were analyzed as DeNovo assembly using the software PEAKS 
(Bioinformatics solutions Inc.).
Bacterial strains. Wild type P. aeruginosa PAO1 (ATCC 15692) and its isogenic mucA mutant PAO1ΔmucA 
strain (lab strain) were grown in LB medium at 37 °C. As standard conditions, E. coli BL21 and TOP10 strains 
were cultured at 37 °C in LB with the respective antibiotics added (50 µg/ml kanamycin).
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Proteins expression and purification. Synthetic genes encoding for Hypothetical protein 
(WP_012026046.1), Alg2A (AEB69783.1), AlyA1 (WP_013992548.1), A1-II (AGJ83952.1), A1-III (BAB03312.1) 
and A1-II´ (BAD16656.1) were ordered from GenScript. Then, they were cloned using Gibson assembly into 
pETM14, which results in a His-tag on the C-terminus of the protein. Expression was performed in E. coli BL21 
and induction was performed at 16 °C with 1 mM of IPTG overnight. Two purification steps were performed: a 
nickel affinity chromatography followed by a desalting PD10 column, both in the 50 mM Tris pH 7.4, 300 mM 
NaCl, 10% glycerol, and 2 mM DTT. Proteins were analyzed by SDS gel electrophoresis.
Halo test assay. For the halo test the P. aeruginosa PAO1 wt cells were grown on agar plates with 
Pseudomonas isolation medium (PI medium) (Bactopeptone 20 g/l, MgCl2 1.4 g/l, K2SO4 10 g/l, glycerol 1%, pH 
7.2). First the Petri dish was seeded with 1 ml of a bacterial culture (OD600=0.8) and paper disks (MDB-oxoid 
CT0998-B) were placed on the agar. Then, the disks were soaked with 10 µl of alginate lyase solution (17.5, 8.75 
and 4.375 pmols) and the plates incubated for 16 hours at 37 °C. Formation of halos was then evaluated by visual 
inspection and direct measurement of halo diameter. Image J program was used to calculate the diameter of halos 
obtained from pictures and measured in pixels.
Measurements of activity by UV assay. Activity of the alginate lyase was determined by the increase 
in absorbance at 235 nm due to the formation of a carbon-carbon double bond at the end of the product gen-
erated from lyase-mediated cleavage of alginate. Three different substrates were tested: brown seaweed alginate 
(Sigma# W201502 A straight-chain, hydrophilic, colloidal, polyuronic acid composed of glucuronic and mannu-
ronic acid residues), ELICITYL # DP25-DP45 Guluronate oligosaccharides (polyG) and ELICITYL # DP20-DP35 
Mannuronate oligosaccharides (polyM).
The substrates were dissolved in a solution of 20% glycerol and 20 mM Tris pH 7.4 so as to reach a final algi-
nate concentration of 0.2%. Then, 50 µL of these substrates were added to the wells containing 7.1 pmol of each 
enzyme. As positive control we used 10 pmols of Sigma A1603 alginase. Absorbance was measured at 235 nm 
every 2 minutes for 78 minutes using UV-star microplates, 96wells, (Greiner #655801).
Biofilm cultivation in flow cell chambers and microscopy. P. aeruginosa biofilms were grown in LB 
medium supplemented with 0.2% glucose at 20 °C in flow cell chambers as was previous described56,57. After 
96 h the mature biofilm was treated with different alginate lyases for 12 h. For analysis, the biofilm was stained 
using the LIVE/DEAD BacLight Bacterial Viability kit (Thermo Scientific) and visualized with a Zeiss LSM 800 
confocal laser scanning microscope (CSLM) using the 20×/0.8 objective with excitation wavelengths of 488 and 
560 nm. Microscope images were processed with the ImageJ analysis software and COMSTAT 2, a specific biofilm 
analysis software was used to quantify the biofilm biomass, thickness and roughness58.
Antimicrobial activity of alginate lyases. P. aeruginosa PAO1 wt and PAO1 ∆mucA were grown until 
an optical density (OD550 nm) of 0.1 was reached and then plated in a microtiter plate (Corning 3596 Polystyrene 
Flat Bottom 96 Well Corning, NY, USA). The different alginases were added at a similar concentration to the one 
used in the biofilm analysis (7.09 pmol/µl). Bacterial growth at 37 °C and 150 rpm was monitored for 8 hours, 
and the absorbance measured at 550 nm every 15 minutes in an SPARK Multimode microplate reader (Tecan, 
Männedorf, Switzerland).
Statistical analysis. Values are expressed as mean ± standard deviation (SD). Statistical analyses were per-
formed using GraphPad Prism 6.00 (GraphPad Software, San Diego, CA, USA) software package. Single com-
parisons were performed with Welch’s correction. A value of p < 0.05 was considered as statistically significant.
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